Gaush Meditech Ltd. (HK:2407) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Gaush Meditech Ltd has signed an agreement with Geuder AG to introduce and localize advanced technology for phacoemulsification and vitrectomy surgery systems in China, aiming to address the growing number of cataract and vitreoretinal disease cases. This move is expected to enrich the company’s product portfolio in ophthalmic surgery and enhance its R&D and production capabilities. The technology, which has been predominantly imported, signals a significant step towards domestic production and potential market growth.
For further insights into HK:2407 stock, check out TipRanks’ Stock Analysis page.